Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Current Deferred Revenue: 2020-2023

Historic Current Deferred Revenue for SAB Biotherapeutics (SABS) over the last 3 years, with Dec 2023 value amounting to $1.3 million.

  • SAB Biotherapeutics' Current Deferred Revenue fell 92.95% to $114,698 in Q3 2024 from the same period last year, while for Sep 2024 it was $114,698, marking a year-over-year decrease of 92.95%. This contributed to the annual value of $1.3 million for FY2023, which is N/A change from last year.
  • Latest data reveals that SAB Biotherapeutics reported Current Deferred Revenue of $1.3 million as of FY2023, which was up 1,222.41% from $100,000 recorded in FY2021.
  • In the past 5 years, SAB Biotherapeutics' Current Deferred Revenue registered a high of $1.3 million during FY2023, and its lowest value of $100,000 during FY2020.
  • Moreover, its 2-year median value for Current Deferred Revenue was $711,205 (2021), whereas its average is $711,205.